Nasdaq:BGLCInvestor relations
A factual view of BGLC's operating businesses, technology relationships, public reporting and governance information.
Investor overview
Find BGLC's financial reporting, public disclosures, business information, healthcare investments and material company developments.
Current financial context
BGLC's recent operating results reflect significant disruption at Chemrex and ongoing investment in recovery and development activities. Investors should review the latest quarterly results, liquidity discussion, internal-control disclosures and risk factors in BGLC's SEC filings.
Capital allocation & treasury
Summarized from the Form 10-Q for the quarter ended June 30, 2026 (opens in a new tab) and stated as of that date.
The Board approved an Ethereum-focused treasury strategy in March 2025, which BGLC describes as a key element of its capital management approach; its Investment Holding segment is to encompass these treasury activities. BGLC did not hold digital assets as of June 30, 2026, while management reviews proposals and cash allocation strategies.
Chemrex continued to derive substantially all of its revenue from industrial chemical trading. The Board has authorized management to explore potential contract development and manufacturing opportunities; that authorization does not commit BGLC to a definitive transition.
Milestones
Each item restates a target or deadline from the cited filing or furnished release. It is not an update on whether the target has since been met.
BGLC and Fidelion are transferring and localizing operating documentation and planning laboratory verification, validation and regulatory and commercial preparation in Malaysia and Singapore. Subject to that work and applicable approvals, BGLC stated it continues to target initial deployment in select Southeast Asian medical hubs during 2026. VitaGuard had not begun generating revenue for BGLC as of June 30, 2026.
July 28, 2026 release (Form 8-K) (opens in a new tab)The Form 10-Q for the quarter ended June 30, 2026 stated that MRNA Scientific had built an enterprise version of GeneMatrix Systems, completed internal workflow testing, and was targeting an initial release of a new report-presentation system during the third quarter of 2026, subject to security, privacy, validation, regulatory and management review.
Form 10-Q, quarter ended June 30, 2026 (opens in a new tab)Under the October 5, 2026 agreement, RYET is required to deliver the technology by December 4, 2026, followed by BGLC acceptance testing. Closing remains subject to technology acceptance, due diligence and required approvals; either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
October 7, 2026 Form 8-K (opens in a new tab)Strategic oncology relationship
At the November 2025 closing, BGLC acquired an approximately 15% interest in Fidelion as part of a reciprocal equity investment and ASEAN licensing transaction. The percentage is stated as of that closing and may change over time.
In turn, Fidelion and its controlling persons reported beneficial ownership of approximately 13.4% of BGLC's common stock, held directly by Fidelion, in a Schedule 13G filed October 22, 2026 (opens in a new tab). That percentage is based on the shares outstanding reported in BGLC's Form 10-Q for the quarter ended June 30, 2026.
As of the November 2025 transaction closing. Complete terms, consideration and related-party disclosures are in BGLC's filed transaction documents.
The executed agreement grants BGLC an exclusive, perpetual and irrevocable license within the defined Southeast Asia territory, subject to its terms.
Regional deployment remains subject to technical validation, regulatory requirements, laboratory implementation and commercial execution.
The transaction documents designate Mr. Su-Leng Tan Lee to serve as Fidelion's initial Chief Executive Officer. Additional related-person information is available in BGLC's SEC filings (opens in a new tab).
Latest SEC filings
Annual reports and quarterly results.
→02Direct access to regulatory filings.
→03Dated company announcements and event information.
→04Board oversight and governance resources.
→05Market, shareholder and contact information.
→06Contact the investor-relations team.
→BGLC's SEC filings are the authoritative source for its financial condition, ownership relationships, material agreements, risks and governance disclosures. This page is general corporate information and is not an investment recommendation or offer.
Statements on this page about plans, expectations and future events are forward-looking statements that involve risks and uncertainties, and actual results may differ materially. See the forward-looking statements notice and the risk factors in BGLC's SEC filings.
